EN DE

Bluestar Adisseo Company (600299) Fair Value & Analysis

Basic Materials · CN · Market cap 26.0B CNY

BA Bluestar Adisseo Company 600299 · SHG
Price¥8.45
Fair Value¥5.94
Upside-29.7%
Quality51/100
Watch Bluestar Adisseo Company for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Thin margins · 5.7% net margin
Low debt · negative free cash flow
1.74% dividend yield
Ranks above peers (8/13)
Narrow moat 38/100
Evidence: High Range ¥4.78 – ¥7.73 Share as image

Fair value as of: Aug 8, 2026

From 16 valuation models · updated 2 days ago

Fair value updated Aug 8, 2026, revised from ¥6.07 to ¥5.94 (−2.1%) since Jul 11, 2026. Share price +8.6% over the past month.

A solid business, but screening 30% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥7.73). The favourable scenario is already priced in.
  • Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥15.46 ¥6.75 Fair Value ¥5.94 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.

How to read this chart

60‑month range ¥6.75 – ¥15.46 · fair‑value band ¥4.78 – ¥7.73 · the ¥8.45 price screens above the ¥5.94 fair value. Dashed = 300-day average. As of Aug 8, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Bluestar Adisseo Company (600299) currently trades at ¥8.45, while our model-based Fair Value estimate is ¥5.94, implying the stock looks roughly 29.7% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Bluestar Adisseo Company generated revenue of 17.3B CNY at a net margin of 5.7%. Revenue grew 2.4% year over year. It earns a return on equity of 5.6%. The balance sheet holds a net cash position of 2.4B CNY. Fundamentals as of Aug 8, 2026

Our scenario range runs from ¥4.78 (bear case) to ¥7.73 (bull case); at ¥8.45, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -30%, 600299 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Residual Income ¥5.08 ¥5.25 ¥5.28 76
ROIC Compounder ¥4.77 ¥5.42 ¥5.99 72
Gordon GGM ¥1.72 ¥3.59 ¥5.69 70
All 16 models by family
Earnings-Based
Graham-Dodd ¥2.55 ¥10.87 ¥14.85 54
Lynch FV ¥2.78 ¥3.97 ¥5.16 50
PEG = 1.0 ¥2.78 ¥3.97 ¥5.16 46
EPV ¥4.77 ¥5.42 ¥5.99 59
Dividend Discount
Gordon GGM ¥1.72 ¥3.59 ¥5.69 70
DDM Multi-Stage ¥1.72 ¥3.02 ¥3.76 61
Multiples
P/E Multiple ¥4.78 ¥6.37 ¥7.97 63
P/S Multiple ¥4.78 ¥6.37 ¥7.97 58
P/B Multiple ¥4.78 ¥6.37 ¥7.97 55
EV/EBIT ¥6.58 ¥8.48 ¥10.39 53
EV/EBITDA ¥8.78 ¥11.41 ¥14.05 54
EV/Revenue ¥5.82 ¥7.94 ¥10.06 43
Asset-Based
NCAV (Graham) ¥3.22 ¥4.32 ¥6.45 50
Economic Profit
Residual Income ¥5.08 ¥5.25 ¥5.28 76
ROIC Compounder ¥4.77 ¥5.42 ¥5.99 72
Growth Earnings
Growth-Adj P/E ¥4.16 ¥5.94 ¥7.73 68

Widest divergence: Multiples (¥6.37) versus Dividend Discount (¥3.02). Highest evidence: Residual Income (76).

Key figures & financial health

Revenue (TTM) 17.3B CNY
Revenue growth (YoY) +2.4%
Net margin 5.7%
Return on equity 5.6%
Free cash flow −372M CNY FY2025
P/E ratio 23.5
More key figures
Operating margin 8.9%
EPS (TTM) ¥0.3600
Dividend yield 1.7%
EPS growth (YoY) -41.2%
Net cash 2.4B CNY FY2025

Figures from reported company fundamentals · as of Aug 8, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 51/100

Of which business quality 54 · Market factors (momentum, volatility) 30

Profitability 36
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 45
Earnings quality: real cash, not paper profit
Fin. Strength 86
Balance sheet, leverage, solvency risk
Investment 35
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 12
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 81
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Bluestar Adisseo Company, together with its subsidiaries, engages in the research, development, production, and sale of poultry, ruminant, swine, and aquaculture nutrition additives.

Full company description

Bluestar Adisseo Company, together with its subsidiaries, engages in the research, development, production, and sale of poultry, ruminant, swine, and aquaculture nutrition additives. The company also offers mycotoxin management and palatability comprising, Unike Plus, Unike, Oxy-Nil, Mold-Nil, Salmo-Nil, Toxy-Nil, Krave AP, Optisweet, Gusti Plus, Maxarome, Delistart, Pepsea, Nutri-Bind Aqua, and Oxy-Nil Aqua Zero; enzymes and emulsifiers, including Rhodimet AT88 and Rhodimet; antioxidants and health by nutrition products, comprising Rhodimet AT88, Rhodimet NP99, Microvit A Supra 1000, and Microvit E Promix 50; milk production product, such as MetaSmart; and sulfur-based products, which includes Rhodimet AT88, Rhodimet® NP99, Microvit A Supra 1000, and Microvit E Promix 50. In addition, the company offers mycotoxin management products, such as Unike Plus, Unike, Toxy-Nil, Krave AP, Optisweet, Gusti Plus, Maxarome, and Delistart, as well as essential nutrient products, such as Rhodimet AT88, a hydroxy-methionine in liquid form; and Microvit A Supra 1000 to deliver performance; Microvit E Promix 50, a specialized nutritional supplement of vitamin E; and AdiSodium, which helps monogastrics to livestock management. Further, it provides various services consisting of PNE, a near infra-red spectroscopy technology; MYCOMAN for the management of mycotoxins; ADICT, a nutritional values calculation tool; Predictor, a tool to help extract the value from feed; E.lab, a broad range of laboratory analyses to help feed and premix producers control the quality of raw materials and additives; DIM, a full support program; MilkPay calculator; Milk$MART; and NESTOR, which is used to formulate net energy. It operates in China, Europe, the Middle East, Africa, the Indian subcontinent, North and south America, the Asia-Pacific regions. The company was founded in 1939 and is based in Beijing, China. Bluestar Adisseo Company operates as a subsidiary of China National Bluestar (Group) Co,Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Bluestar Adisseo Company reported revenue of ¥17.2B in FY2025 versus ¥12.9B in FY2021, a compound +7.6%/yr. Reported net income was ¥1.2B in FY2025, compounding −5.9%/yr from FY2021.

Growth Quality 37/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
17.2B CNY
Latest YoY
+10.9%
Avg. growth/yr (3Y)
+5.8%
Avg. growth/yr (5Y)
+7.7%
Avg. growth/yr (28Y)
+16.5%
Revenue +7.6%/yr
FY21 ¥12.9B
FY22 ¥14.5B
FY23 ¥13.2B
FY24 ¥15.5B
FY25 ¥17.2B
Net income −5.9%/yr
FY21 ¥1.5B
FY22 ¥1.2B
FY23 ¥52.2M
FY24 ¥1.2B
FY25 ¥1.2B

600299 screens 30% overvalued. Compare with Linde plc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Bluestar Adisseo Company Fair Value". https://www.fairvalue-calculator.com/stock/600299

Peer Group

Specialty Chemicals · 676 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 51 · Below median
Fair Value upside −30% · Below median
Return on equity (TTM) 6% · Below median
Return on assets 4% · Above median
Net margin (TTM) 6% · Above median
Operating margin (TTM) 9% · Above median
Revenue growth 2% · Below median
Dividend yield (TTM) 1.7% · Above median
Debt / equity 0.08× · Lower than median

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

P/E (TTM) 23.5× · Cheaper than median
P/B 1.31× · Cheaper than median
P/S (TTM) 1.50× · Pricier than median
EV/EBITDA 8.0× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 12 · sector 19
PAST 22 · sector 23
HEALTH 96 · sector 95
DIVIDEND 35 · sector 25

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN $489.98 $222.03 -55%
Nan Ya Plastics Corporation 1303 181.50 TWD 255.83 TWD +41%
Wanhua Chemical Group 600309 ¥70.04 ¥68.03 -3%
Novozymes A/S NSISB kr 428.20 kr 179.66 -58%
Asian Paints Limited ASIANPAINT ₹2,689 ₹668.81 -75%
Solar Industries India Limited SOLARINDS ₹18,236 ₹2,793 -85%
Pidilite Industries Limited PIDILITIND ₹1,560 ₹351.84 -77%
PT Chandra Asri Pacific Tbk TPIA 1,805 IDR 2,888 IDR +60%
Linde India Limited LINDEINDIA ₹7,115 ₹757.93 -89%
Berger Paints India Limited BERGEPAINT ₹493.70 ₹164.29 -67%

Compare Bluestar Adisseo Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Bluestar Adisseo Company (600299) overvalued or undervalued?
As of Aug 8, 2026, our model estimates a fair value of ¥5.94 versus a price of ¥8.45, about −30% (overvalued).
What is the fair value of 600299?
Our model-based fair value for Bluestar Adisseo Company is ¥5.94 (as of Aug 8, 2026), built from audited fundamentals. The current price is ¥8.45.
What is the quality score of 600299?
Bluestar Adisseo Company has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Bluestar Adisseo Company (600299)?
Bluestar Adisseo Company reported trailing-twelve-month revenue of about 17.3B CNY (latest available figure, as of Aug 8, 2026).
What is the net profit margin of 600299?
The net profit margin of Bluestar Adisseo Company is about 5.7%, meaning it keeps roughly 5.7% of revenue as net income. Based on the latest reported figures.
Does Bluestar Adisseo Company pay a dividend?
Bluestar Adisseo Company currently shows a dividend yield of about 1.49% relative to its recent price (as of Aug 8, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Bluestar Adisseo Company and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.